We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+11.29%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$244M
AUM Growth
+$29.9M
Cap. Flow
+$6.34M
Cap. Flow %
2.6%
Top 10 Hldgs %
46.31%
Holding
78
New
4
Increased
21
Reduced
24
Closed
3

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$3.4M
2
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$2.69M
3
BLUE
bluebird bio
BLUE
+$2.63M
4
ZGNX
Zogenix, Inc.
ZGNX
+$2.06M
5
LOXO
Loxo Oncology, Inc
LOXO
+$1.85M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$2.23M
2
NERV icon
Minerva Neurosciences
NERV
+$977K
3
LMNX
Luminex Corp
LMNX
+$945K
4
LRMR icon
Larimar Therapeutics
LRMR
+$784K
5
ATRC icon
AtriCure
ATRC
+$684K

Sector Composition

Rank Sector Weight
1 Healthcare 88.76%
2 Financials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
51
DELISTED
Cidara Therapeutics
CDTX
$936K 0.38%
10,638
– –
OBSV
52
DELISTED
ObsEva SA Ordinary Shares
OBSV
$781K 0.32%
43,338
-21,639
-33% -$318K
VIRX
53
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$747K 0.31%
10,677
– –
SPRO icon
54
Spero Therapeutics
SPRO
$67.7M
$736K 0.3%
+70,000
New +$812K
URGN icon
55
UroGen Pharma
URGN
$1.86B
$708K 0.29%
15,000
+5,000
+50% +$232K
CYTK icon
56
Cytokinetics
CYTK
$10.5B
$617K 0.25%
62,690
-6,747
-10% -$54.1K
RIGL icon
57
Rigel Pharmaceuticals
RIGL
$681M
$442K 0.18%
13,760
– –
NTGN
58
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$427K 0.18%
50,000
– –
APTX
59
DELISTED
Aptinyx Inc. Common Stock
APTX
$420K 0.17%
14,500
-10,500
-42% -$255K
STRO icon
60
Sutro Biopharma
STRO
$401M
$412K 0.17%
+2,749
New +$415K
ASMB icon
61
Assembly Biosciences
ASMB
$498M
$396K 0.16%
+889
New +$416K
KALV
62
DELISTED
KalVista Pharmaceuticals
KALV
$392K 0.16%
+17,725
New +$240K
MASI
63
DELISTED
Masimo
MASI
$374K 0.15%
3,000
-2,000
-40% -$222K
RDUS
64
DELISTED
Radius Health, Inc.
RDUS
$365K 0.15%
20,500
+10,500
+105% +$238K
NERV icon
65
Minerva Neurosciences
NERV
$185M
$338K 0.14%
3,363
-12,996
-79% -$977K
SLGL icon
66
Sol-Gel Technologies
SLGL
$269M
$263K 0.11%
3,500
– –
LCTX icon
67
Lineage Cell Therapeutics
LCTX
$269M
$235K 0.1%
114,300
-93,269
-45% -$196K
KDMN
68
DELISTED
Kadmon Holdings, Inc.
KDMN
$210K 0.09%
63,000
-2,500
-4% -$8.87K
BLCM
69
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$185K 0.08%
3,000
– –
NEOS
70
DELISTED
Neos Therapeutics, Inc
NEOS
$133K 0.05%
27,500
– –
DERM
71
DELISTED
Dermira, Inc.
DERM
$55K 0.02%
5,000
-18,000
-78% -$182K
GLMD icon
72
Galmed Pharmaceuticals
GLMD
$5.13M
– –
-278
Closed -$595K
ONC
73
BeOne Medicines Ltd
ONC
$32.8B
– –
-2,000
Closed -$307K
FTSV
74
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-10,000
Closed -$160K
1 2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, DAFNA Capital Management held 78 positions worth $244M, up 14% from $214M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

DAFNA Capital Management's Q3 2018 filing shows 4 new, 21 increased, 24 reduced and 3 closed positions. Its largest new stake was Spero Therapeutics: 70,000 shares worth $736K. The largest sale was DexCom, an estimated $2.23M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier, followed by Financials.

  • DAFNA Capital Management's largest Q3 2018 buy was Spero Therapeutics: 70,000 shares worth $736K.
  • DAFNA Capital Management added most to argenx in Q3 2018, an estimated $3.4M increase.
  • DAFNA Capital Management's biggest Q3 2018 reduction was DexCom, cutting an estimated $2.23M.
  • DAFNA Capital Management fully exited Galmed Pharmaceuticals in Q3 2018, selling an estimated $595K.
  • DAFNA Capital Management's ten largest holdings make up 46% of its $244M portfolio in Q3 2018.
  • DAFNA Capital Management opened 4 new positions and closed 3 in Q3 2018.
  • DAFNA Capital Management's portfolio value rose 14% quarter-over-quarter to $244M.

Based on DAFNA Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.